Trial · NCT06387121
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
NCT06387121, Phase 2, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL. Trials, record NCT06387121. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06387121
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- NCT number
- NCT06387121
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 53 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Interventions
- Vincristine, Cyclophosphamide, Dexamethasone, Venetoclax, Inotuzumab ozogamicin, Blinatumomab, 6-mercaptopurine, Methotrexate, Cytarabine, Prednisone
- First posted
- 2024-04-26
- Last updated
- 2025-12-17
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | MRD-negative complete remission rate measured by flow cytometry. | After induction (4 week) | No immature cells were detected by flow cytometry when CR criteria were met after induction therapy. |
| Secondary | Complete remission (CR) rate | an expected average of 3 months | |
| Secondary | Overall survival (OS) | Up to 5 years post-registration | From the date of registration to the date of death resulting from any cause. |
| Secondary | Relapse free survival (RFS) | Up to 5 years post-registration | From the date of complete remission (CR) until the date of documented relapse or death due to any cause or last follow-up. |
| Secondary | Disease-free Survival (DFS) | Up to 5 years post-registration | From CR1 to relapse, death from any cause or last follow-up. |
| Secondary | Mortality | Day 30 and Day 60 of induction therapy initiation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06387121
GET https://conductscience.org/api/trials/v1/NCT06387121/registered